Orchard Therapeutics (ORTX) Received its Third Buy in a Row


After Wedbush and J.P. Morgan gave Orchard Therapeutics (NASDAQ: ORTX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Orchard Therapeutics today and set a price target of $16.00. The company’s shares closed last Thursday at $7.01.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 62.4% and a 64.6% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Orchard Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.00.

See today’s analyst top recommended stocks >>

Based on Orchard Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2 million and GAAP net loss of $20.29 million. In comparison, last year the company earned revenue of $1.92 million and had a GAAP net loss of $36.74 million.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ORTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Read More on ORTX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts